Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Scott J. Keating"'
Autor:
Christopher Parker, Fei Fei Liu, Kristen A. Deger, Conrado Franco-Villalobos, Irina Proskorovsky, Scott J. Keating, Sonja Sorensen
Publikováno v:
Advances in Therapy. 40:2355-2374
Publikováno v:
Blood. 140:10921-10923
Publikováno v:
Transplantation and Cellular Therapy. 29:59.e1-59.e6
Chimeric antigen receptor (CAR) T-cell therapies demonstrated efficacy in relapsed/refractory large B-cell lymphoma (LBCL) but are associated with cytokine release syndrome (CRS) and neurological events (NE). We wanted to estimate the total cost of C
Publikováno v:
Journal of Clinical Oncology. 40:19-19
19 Background: MCL is an aggressive form of non-Hodgkin’s lymphoma with an incidence of 1 in 200,000 in the United States. Limited evidence exists on real-world tx utilization, costs, and survival outcomes associated with MCL among older pts in the
Autor:
Donald Patrick, Shauna McManus, Lauren Podger, Ashley Saunders, Julia Braverman, Fei Fei Liu, Scott J. Keating
Publikováno v:
Journal of Clinical Oncology. 40:294-294
294 Background: TRANSCEND NHL 001 (TRANSCEND; NCT02631044) evaluated efficacy and safety of the CAR T cell therapy lisocabtagene maraleucel (liso-cel) as third-line or later treatment in patients with R/R LBCL. Prior research demonstrated improvement
Autor:
November McGarvey, Corey Pelletier, John E. Godwin, James Lymp, Matthew Gitlin, M. Lia Palomba, Monika Parisi Jun, Andy Nguyen, Scott J Keating
Publikováno v:
Leuk Lymphoma
This retrospective study estimated postinfusion health care resource utilization (HCRU) by site of care among 303 patients with relapsed/refractory large B-cell lymphoma who received third- or later-line treatment with lisocabtagene maraleucel (liso-
Publikováno v:
Transplantation and Cellular Therapy. 28:404.e1-404.e6
The use of chimeric antigen receptor (CAR) T-cell therapy after a second relapse of diffuse large B-cell lymphoma (DLBCL) has shown favorable efficacy in clinical trials; however, little is known about health care resource utilization (HCRU) and cost
Autor:
Conrado Franco-Villalobos, Kristen Deger, Irina Proskorovsky, Sonja Sorensen, Scott J Keating, Emily Dorman, Christopher Parker, Fei Fei Liu
Publikováno v:
Blood. 138:3003-3003
Background: Patients with R/R LBCL after primary treatment have historically had a poor prognosis and few treatment options. Prior research found that the chimeric antigen receptor (CAR) T cell therapy, axi-cel may be cost-effective in comparison wit
Autor:
John Brokars, Brian Stwalley, Elias Jabbour, Ronda Copher, Arianna Kee, Bruce Feinberg, Andrew J Klink, Scott J Keating
Publikováno v:
Blood. 136:1-2
Introduction: The safety and efficacy of 1L dasatinib and 1L imatinib was established in the pivotal DASISION and IRIS trials; however, limited real-world evidence exists for the comparative effectiveness of these agents among US patients with CP-CML
Autor:
Kathryn S. Kolibaba, John Brokars, Jie Zhou, Jamyia Clark, Brian Stwalley, Scott J Keating, Ronda Copher, Elias Jabbour, Arianna Kee
Publikováno v:
Blood. 136:36-37
Introduction:Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the unregulated proliferation of myeloid cells in the bone marrow and their accumulation in the blood. The approval of imatinib (IM) and second-generation T